[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1195512A1 - Polysaccharide protein conjugate vaccines - Google Patents

Polysaccharide protein conjugate vaccines

Info

Publication number
HK1195512A1
HK1195512A1 HK14109137.9A HK14109137A HK1195512A1 HK 1195512 A1 HK1195512 A1 HK 1195512A1 HK 14109137 A HK14109137 A HK 14109137A HK 1195512 A1 HK1195512 A1 HK 1195512A1
Authority
HK
Hong Kong
Prior art keywords
protein conjugate
conjugate vaccines
polysaccharide protein
polysaccharide
vaccines
Prior art date
Application number
HK14109137.9A
Other languages
Chinese (zh)
Inventor
車恒.羅伯特.李
卡爾.
.弗拉施
Original Assignee
美國政府健康及人類服務部
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國政府健康及人類服務部 filed Critical 美國政府健康及人類服務部
Publication of HK1195512A1 publication Critical patent/HK1195512A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK14109137.9A 2003-08-06 2014-09-10 Polysaccharide protein conjugate vaccines HK1195512A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49338903P 2003-08-06 2003-08-06

Publications (1)

Publication Number Publication Date
HK1195512A1 true HK1195512A1 (en) 2014-11-14

Family

ID=34135243

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14109137.9A HK1195512A1 (en) 2003-08-06 2014-09-10 Polysaccharide protein conjugate vaccines

Country Status (9)

Country Link
US (1) US9173931B2 (en)
EP (4) EP2366403B1 (en)
CN (4) CN100423774C (en)
AU (2) AU2004281630A1 (en)
BR (2) BRPI0413323B8 (en)
CA (4) CA2535043A1 (en)
HK (1) HK1195512A1 (en)
WO (2) WO2005014037A2 (en)
ZA (2) ZA200601688B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
WO2005014037A2 (en) 2003-08-06 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
JP5718545B2 (en) * 2004-04-30 2015-05-13 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Neisseria meningitidis conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2005249571B9 (en) * 2004-06-04 2011-01-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing immunogenic conjugates
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
PT1868645E (en) 2005-04-08 2012-05-17 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2612980C (en) * 2005-06-27 2019-01-15 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising a haemophilus influenzae type b saccharide conjugate
KR101711903B1 (en) * 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Methods for preparing complex multivalent immunogenic conjugates
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2043692B1 (en) 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
US8003112B2 (en) 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
BR112012009014B8 (en) * 2009-09-30 2022-10-04 Novartis Ag PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION
ES2707778T3 (en) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Immunogens polysaccharides conjugated with carrier proteins of E. coli
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102526724B (en) * 2011-01-14 2015-07-22 四川大学 Aluminum hydroxide gel-polysaccharide composite immunologic adjuvant and preparation method and application thereof
CN104428008B (en) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) Multivalent meningococcal conjugates and methods of making conjugates
EP2724730A1 (en) 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US10105431B2 (en) 2014-01-21 2018-10-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
CN104198725B (en) * 2014-08-14 2016-04-06 上海睿康生物科技有限公司 Cyclic citrullinated peptid detection kit
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
PE20180460A1 (en) 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd METHODS TO IMPROVE THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND A MULTIVALENT VACCINE FORMULATION OBTAINED THROUGH THE SAME
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
PT3506935T (en) 2016-09-02 2024-04-01 Sanofi Pasteur Inc Neisseria meningitidis vaccine
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN111132691A (en) 2017-06-10 2020-05-08 创赏有限公司 Multivalent conjugate vaccines with divalent or multivalent conjugate polysaccharides providing improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2019126197A1 (en) 2017-12-18 2019-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
CN108525003A (en) * 2018-03-13 2018-09-14 中山大学 Based on the double cross of acylhydrazone key and hydrophobe self assembly connection hybridized hydrogel, preparation method and skin histology wound repair agent
CN108498847A (en) * 2018-03-13 2018-09-07 中山大学 Macromolecule hydrogel, preparation method based on acylhydrazone key and skin histology adhesive
CN109001198A (en) * 2018-09-03 2018-12-14 艾美卫信生物药业(浙江)有限公司 The method that the NaTDC precipitation method detect free polysaccharide in Hib combined vaccine
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CN113274489B (en) * 2021-04-30 2023-08-29 山东省药学科学院 Chitin oligosaccharide vaccine for preventing fungal infection and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DK163176C (en) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst POISONOUS CONJUGATE VACCINE AGAINST INFECTIONS OF PSEUDOMONA'S AERUGINOSA AND ESCHERICHIA COLI BACTERIES, METHOD OF PRODUCING IT AND USING THE VACCINE
JPS63295408A (en) * 1987-05-28 1988-12-01 Mitsubishi Gas Chem Co Inc Method for purifying aqueous hydrazine hydrate solution
US5066408A (en) * 1990-03-15 1991-11-19 Powell Jonathan S Means and method to treat swimming pool water
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5480643A (en) * 1991-10-16 1996-01-02 Ecolab Inc. Stable antimicrobial dialdehyde composition and methods of use
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
WO1996029094A1 (en) * 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
AU4769701A (en) * 2000-03-22 2001-10-03 Solulink Inc Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US20050014037A1 (en) * 2002-12-04 2005-01-20 Chris Boyer Fuel cell with recombination catalyst
WO2005014037A2 (en) 2003-08-06 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines

Also Published As

Publication number Publication date
EP2366403B1 (en) 2014-10-08
CN102151331B (en) 2013-10-30
EP2366404A2 (en) 2011-09-21
CN1863553B (en) 2011-05-04
BRPI0413309A (en) 2006-10-10
EP1651261B1 (en) 2014-10-08
CA2844154A1 (en) 2005-02-17
CN103623405A (en) 2014-03-12
EP1651262A2 (en) 2006-05-03
EP2366404A3 (en) 2012-03-14
CN102151331A (en) 2011-08-17
CN1863553A (en) 2006-11-15
CN1863554A (en) 2006-11-15
EP2366403A2 (en) 2011-09-21
BRPI0413323B8 (en) 2021-05-25
CA2534870A1 (en) 2005-02-17
WO2005037320A3 (en) 2006-01-05
WO2005014037A3 (en) 2006-01-26
BRPI0413323B1 (en) 2019-09-10
CN100423774C (en) 2008-10-08
US20070110762A1 (en) 2007-05-17
EP2366403A3 (en) 2012-03-14
AU2004263135A1 (en) 2005-02-17
BRPI0413309B1 (en) 2019-10-01
EP1651261A2 (en) 2006-05-03
WO2005014037A2 (en) 2005-02-17
AU2004263135B2 (en) 2010-11-25
CA2844154C (en) 2016-12-20
WO2005037320A2 (en) 2005-04-28
EP2366404B1 (en) 2014-11-19
CN103623405B (en) 2016-06-15
US9173931B2 (en) 2015-11-03
CA2535043A1 (en) 2005-04-28
CA2534870C (en) 2014-05-06
BRPI0413323A (en) 2006-10-10
ZA200601688B (en) 2007-05-30
CA2948114A1 (en) 2005-02-17
ZA200601689B (en) 2007-12-27
CA2948114C (en) 2019-02-26
AU2004281630A1 (en) 2005-04-28
BRPI0413309B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
HK1195512A1 (en) Polysaccharide protein conjugate vaccines
AU2003257003A8 (en) Chimeric multivalent polysaccharide conjugate vaccines
HK1204574A1 (en) Multivalent meningococcal derivatized polysaccharide protein conjugates and corresponding vaccines
HK1088529A1 (en) Aseptic combination preparation
GB0329146D0 (en) Vaccine
IL173921A0 (en) Vaccine
SI1592457T1 (en) Folate-vinblastine conjugate as medicament
GB0323840D0 (en) Vaccines
EP1682572A4 (en) Protein expression
GB0305794D0 (en) Vaccine
EP1591451A4 (en) Peptide conjugate
GB0330079D0 (en) Vaccine
GB2420185B (en) Ophthalmoscope
GB0321614D0 (en) Vaccines
GB0304634D0 (en) Vaccines
GB0317376D0 (en) Immunogenic protein and uses thereof
GB0308691D0 (en) Vaccine preparations
AU2003900767A0 (en) Idiotypic vaccine
GB2407395B (en) Ophthalmoscope
GB0330007D0 (en) Vaccines
GB0306445D0 (en) Conjugate
GB0329827D0 (en) Vaccine
GB0305028D0 (en) Vaccine
GB0326757D0 (en) Vaccine
GB0304635D0 (en) Vaccines

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240801